ArticleExperimental and therapeutic medicine2022

Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway.

Yan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.